Cancer Chemotherapy and Pharmacology

, Volume 75, Issue 5, pp 993–1004 | Cite as

Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer

  • Niall TebbuttEmail author
  • Dusan Kotasek
  • Howard A. Burris
  • Lee S. Schwartzberg
  • Herbert Hurwitz
  • Joe Stephenson
  • Douglas J. Warner
  • Lisa Chen
  • Cheng-Pang Hsu
  • David Goldstein
Original Article



This study assessed the safety, efficacy, and pharmacokinetics of motesanib, a multitargeted small molecule angiogenesis inhibitor, with and without panitumumab, in combination with FOLFIRI or FOLFOX in patients with metastatic colorectal cancer (mCRC).


This open-label, phase 1b, two-part, multicenter study in patients with mCRC and ≤1 prior treatment evaluated escalating doses (50, 75, 100, or 125 mg QD, 75 mg BID) of motesanib with panitumumab and chemotherapy (Part 1) and the target dose of motesanib with chemotherapy (Part 2).


At 17 sites in the USA and Australia, 119 patients were enrolled between December 2004 and February 2010. In Part 1 [motesanib plus panitumumab/FOLFIRI (n = 36) or plus panitumumab/FOLFOX (n = 17)], all motesanib doses tested were tolerated and 125 mg QD was deemed the target dose. Following toxicity results for combination therapy in other trials, panitumumab was withdrawn from the study. Part 2 evaluated motesanib 125 mg with chemotherapy [FOLFIRI (n = 37); FOLFOX (n = 29)]. The primary endpoint, objective response rate in patients with measurable disease by RECIST, was 20 % overall and was higher among patients receiving first-line (27 % overall; FOLFOX, 24 %; FOLFIRI, 27 %) compared with second-line therapy (14 % overall; FOLFOX, 0 %; FOLFIRI, 20 %). The most common adverse events were diarrhea, nausea, fatigue, and hypertension. We observed a low rate of cholecystitis [3 of 119 (2.5 %)], a known adverse event of motesanib and other small molecule VEGF inhibitors.


Motesanib 125 mg QD in combination with FOLFIRI or FOLFOX chemotherapy was tolerated and demonstrated modest efficacy in first-/second-line mCRC.


Anti-angiogenic Targeted agent Metastatic colorectal cancer Dose-escalation Motesanib Panitumumab 



This work was sponsored by Amgen Inc. The authors would like to thank Yining Ye for statistical support; Bethlyn Sloey, Shubhada Kulkarni, and Bernd Bruenner, all of Amgen Inc., for their contribution to PK sample and data analysis; and Wanda Krall, Ph.D., whose work was funded by Amgen Inc., for assistance in the preparation of this manuscript.

Supplementary material

280_2015_2694_MOESM1_ESM.docx (250 kb)
Supplementary material 1 (DOCX 250 kb)


  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2013) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. GLOBOCAN 2012 v10, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] Lyon, France: International Agency for Research on Cancer., accessed on 13/12/2013
  2. 2.
    Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30CrossRefPubMedGoogle Scholar
  3. 3.
    NCCN (2014) National Comprehensive Cancer Care Network Clinical Practice Guidelines in Oncology™: colorectal cancer. Version 2.2015
  4. 4.
    Lucas AS, O’Neil BH, Goldberg RM (2011) A decade of advances in cytotoxic chemotherapy for metastatic colorectal cancer. Clin Colorectal Cancer 10:238–244CrossRefPubMedGoogle Scholar
  5. 5.
    Price TJ, Segelov E, Burge M, Haller DG, Ackland SP, Tebbutt NC et al (2013) Current opinion on optimal treatment for colorectal cancer. Expert Rev Anticancer Ther 13:597–611CrossRefPubMedGoogle Scholar
  6. 6.
    Jain VK, Hawkes EA, Cunningham D (2011) Integration of biologic agents with cytotoxic chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer 10:245–257CrossRefPubMedGoogle Scholar
  7. 7.
    Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K et al (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23:2479–2516CrossRefPubMedGoogle Scholar
  8. 8.
    Chu E (2012) An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer 11:1–13CrossRefPubMedGoogle Scholar
  9. 9.
    Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L et al (2006) AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 66:8715–8721CrossRefPubMedGoogle Scholar
  10. 10.
    Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG et al (2008) Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31–42CrossRefPubMedGoogle Scholar
  11. 11.
    Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD et al (2009) Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794–3801CrossRefPubMedGoogle Scholar
  12. 12.
    Benjamin RS, Schoffski P, Hartmann JT, Van Oosterom A, Bui BN, Duyster J et al (2011) Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol 68:69–77CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Blumenschein GR Jr, Reckamp K, Stephenson GJ, O’Rourke T, Gladish G, McGreivy J et al (2010) Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res 16:279–290CrossRefPubMedGoogle Scholar
  14. 14.
    Blumenschein GR Jr, Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT et al (2011) A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 22:2057–2067CrossRefPubMedGoogle Scholar
  15. 15.
    Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L et al (2011) Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 12:369–376CrossRefPubMedGoogle Scholar
  16. 16.
    Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F et al (2012) International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 30:2829–2836CrossRefPubMedGoogle Scholar
  17. 17.
    Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664CrossRefPubMedGoogle Scholar
  18. 18.
    Wainberg Z, Hecht JR (2006) A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. Clin Colorectal Cancer 5:363–367CrossRefPubMedGoogle Scholar
  19. 19.
    Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706–4713CrossRefPubMedGoogle Scholar
  20. 20.
    Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697–4705CrossRefPubMedGoogle Scholar
  21. 21.
    Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR et al (2014) PEAK: A randomized, multicenter phase II study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS Exon 2 metastatic colorectal cancer. J Clin Oncol 32(21):2240–2247. doi: 10.1200/JCO.2013.53.2473 CrossRefPubMedGoogle Scholar
  22. 22.
    Tabernero J (2007) The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5:203–220CrossRefPubMedGoogle Scholar
  23. 23.
    Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D et al (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27:672–680CrossRefPubMedGoogle Scholar
  24. 24.
    Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG et al (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563–572CrossRefPubMedGoogle Scholar
  25. 25.
    Mayer RJ (2007) Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol 25:4165–4167CrossRefPubMedGoogle Scholar
  26. 26.
    Herbst RS, Sandler A (2008) Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. Oncologist 13:1166–1176CrossRefPubMedGoogle Scholar
  27. 27.
    Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM et al (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25:4557–4561CrossRefPubMedGoogle Scholar
  28. 28.
    Van Cutsem E, Bajetta E, Valle J, Kohne CH, Hecht JR, Moore M et al (2011) Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol 29:2004–2010CrossRefPubMedGoogle Scholar
  29. 29.
    Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL et al (2012) Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol 30:3588–3595CrossRefPubMedGoogle Scholar
  30. 30.
    Hecht JR, Trarbach T, Hainsworth JD, Major P, Jager E, Wolff RA et al (2011) Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. J Clin Oncol 29:1997–2003CrossRefPubMedGoogle Scholar
  31. 31.
    Rosen LS, Lipton L, Price TJ, Belman ND, Boccia RV, Hurwitz HI et al (2013) The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. BMC Cancer 13:242CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    Howard SA, Krajewski KM, Thornton E, Jagannathan JP, O’Regan K, Cleary J et al (2012) Decade of molecular targeted therapy: abdominal manifestations of drug toxicities—what radiologists should know. AJR Am J Roentgenol 199:58–64CrossRefPubMedGoogle Scholar
  33. 33.
    Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14:29–37CrossRefPubMedGoogle Scholar
  34. 34.
    Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019CrossRefPubMedGoogle Scholar
  35. 35.
    Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499–3506CrossRefPubMedGoogle Scholar
  36. 36.
    Bendell JC, Bekaii-Saab TS, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H et al (2012) Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist 17:1486–1495CrossRefPubMedCentralPubMedGoogle Scholar
  37. 37.
    Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20:1842–1847CrossRefPubMedGoogle Scholar
  38. 38.
    Infante JR, Reid TR, Cohn AL, Edenfield WJ, Cescon TP, Hamm JT et al (2013) Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study. Cancer 119:2555–2563CrossRefPubMedGoogle Scholar
  39. 39.
    Hochster HS (2013) HORIZON I: is there a future for oral anti-angiogenics on the horizon of colorectal cancer therapy? Br J Cancer 108:477–478CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Niall Tebbutt
    • 1
    Email author
  • Dusan Kotasek
    • 2
  • Howard A. Burris
    • 3
  • Lee S. Schwartzberg
    • 4
  • Herbert Hurwitz
    • 5
  • Joe Stephenson
    • 6
  • Douglas J. Warner
    • 7
  • Lisa Chen
    • 7
  • Cheng-Pang Hsu
    • 7
  • David Goldstein
    • 8
  1. 1.Department of Medical OncologyAustin HealthHeidelbergAustralia
  2. 2.Ashford Cancer CentreAshfordAustralia
  3. 3.Sarah Cannon Research InstituteNashvilleUSA
  4. 4.The West ClinicMemphisUSA
  5. 5.Duke University Medical CenterDurhamUSA
  6. 6.Cancer Center of the CarolinasGreenvilleUSA
  7. 7.Amgen Inc.Thousand OaksUSA
  8. 8.Prince of Wales Clinical School, University of New South WalesPrince of Wales HospitalSydneyAustralia

Personalised recommendations